Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. (Q34491595)

2 August 2017

title

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. (English)

1 reference

2 August 2017

F Gilli

1

1 reference

2 August 2017

F Marnetto

2

1 reference

2 August 2017

M Caldano

3

1 reference

2 August 2017

A Sala

4

1 reference

2 August 2017

S Malucchi

5

1 reference

2 August 2017

M Capobianco

6

1 reference

2 August 2017

A Bertolotto

7

1 reference

2 August 2017

language of work or name

1 reference

1 February 2006

1 reference

Multiple Sclerosis Journal

2 August 2017

published in

1 reference

2 August 2017

volume

12

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

47-57

1 reference

The human intracellular Mx-homologous protein is specifically induced by type I interferons.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

The expression of potency of neutralizing antibodies for interferons and other cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

A novel method for real time quantitative RT-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Interferon-gamma and TRAIL in human breast tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

IFN-gamma enhances TRAIL-induced apoptosis through IRF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Biologic impact of interferon antibodies, and complexities in assessing their clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1245OA

10.1191/135248506MS1245OA

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference